Effect of etanercept (enbrel) on interleukin 6, tumor necrosis factor ", and markers of immune activation in HIV-infected subjects receiving interleukin 2

Beverly E. Sha, Debra M. Ogata-Arakaki, Lawrence Fox, Scharla Estep, Alejo Erice, Patrick Kilgo, Robert E. Walker, Lynne Bancroft, Michael M. Lederman, Hernan Valdez, Rebecca S. Gelman, Alan L. Landay, Jan Agosti, Ronald Mitsuyasu, Richard B. Pollard, Donna Mildvan, Ann Namkung

Research output: Contribution to journalArticle

44 Scopus citations

Abstract

The effect of etanercept, a soluble p75 tumor necrosis factor (TNF) receptor:Fc fusion protein (Enbrel; Immunex, Seattle, WA) on plasma cytokines was evaluated in 11 HIV-infected subjects receiving highly active antiretroviral therapy (HAART) for 28 weeks with or without subcutaneous or intravenous recombinant human interleukin 2 (rhIL-2). Plasma IL-6 and C-reactive protein (CRP) levels increased after rhIL-2 treatment. Etanercept pretreatment attenuated these increases. Median plasma IL-6 levels were 20.29 pg/ml 4 days after rhIL-2 and 7.87 pg/ml 4 days after etanercept and rhIL-2 (p = 0.22); median CRP levels were 78.73 and 46.16 μg/ml, respectively (p = 0.03). An effect on TNF bioactivity could not be assessed as all measurements were below limits of detection. No significant changes were seen in temperature or plasma levels of IL-4, IL-l0, IL-12, interferon γ, or HIV-1 RNA levels. All subjects had undetectable or low-level HIV-1 RNA levels before etanercept dosing. One subject died; however, her death was thought to be unrelated to etanercept. Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further.

Original languageEnglish (US)
Pages (from-to)661-665
Number of pages5
JournalAIDS Research and Human Retroviruses
Volume18
Issue number9
DOIs
StatePublished - 2002
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Sha, B. E., Ogata-Arakaki, D. M., Fox, L., Estep, S., Erice, A., Kilgo, P., Walker, R. E., Bancroft, L., Lederman, M. M., Valdez, H., Gelman, R. S., Landay, A. L., Agosti, J., Mitsuyasu, R., Pollard, R. B., Mildvan, D., & Namkung, A. (2002). Effect of etanercept (enbrel) on interleukin 6, tumor necrosis factor ", and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Research and Human Retroviruses, 18(9), 661-665. https://doi.org/10.1089/088922202760019365